SOX10 Regulates Melanoma Metastasis Through the IRF1-ITGA3/EphA2-FAK Pathway.

IF 4.3 2区 医学 Q1 Medicine
Cancer Science Pub Date : 2025-08-13 DOI:10.1111/cas.70173
Ryuya Kaminaka, Nana Takahashi, Mayu Nishizawa, Soichiro Sasaki, Yuichiro Sugihara, Minoru Matsumoto, Ryoma Taniguchi, Yue Zhou, Yoshihiro Hayakawa, Hiroaki Sakurai, Satoru Yokoyama
{"title":"SOX10 Regulates Melanoma Metastasis Through the IRF1-ITGA3/EphA2-FAK Pathway.","authors":"Ryuya Kaminaka, Nana Takahashi, Mayu Nishizawa, Soichiro Sasaki, Yuichiro Sugihara, Minoru Matsumoto, Ryoma Taniguchi, Yue Zhou, Yoshihiro Hayakawa, Hiroaki Sakurai, Satoru Yokoyama","doi":"10.1111/cas.70173","DOIUrl":null,"url":null,"abstract":"<p><p>Melanoma heterogeneity contributes to increased metastatic potential. Although a subpopulation characterized by MITF<sup>low</sup>/AXL<sup>high</sup> has been linked to invasiveness, the underlying mechanisms remain unclear. In this study, we identified cell migration-related gene sets as significantly enriched after the knockdown of SOX10 in melanoma. Both in silico analysis and in vitro analysis identified ITGA3 and EPHA2 as downstream effectors of SOX10-mediated migration, essential for cell adhesion and random motility, respectively. Moreover, the oncogenic activation of MAPK was necessary for increased random motility through EphA2 phosphorylation at the Ser 897 residue. We also identified IRF1 as an upstream regulator of both ITGA3 and EphA2 after the knockdown of SOX10. Notably, IRF1 suppression or the treatment with the FAK inhibitor, defactinib, significantly reduced melanoma metastasis in vivo. These findings demonstrate that the reduced expression of SOX10 promotes melanoma metastasis through the IRF1-ITGA3/EphA2-FAK pathway and highlight FAK inhibition as a potential therapeutic strategy.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/cas.70173","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Melanoma heterogeneity contributes to increased metastatic potential. Although a subpopulation characterized by MITFlow/AXLhigh has been linked to invasiveness, the underlying mechanisms remain unclear. In this study, we identified cell migration-related gene sets as significantly enriched after the knockdown of SOX10 in melanoma. Both in silico analysis and in vitro analysis identified ITGA3 and EPHA2 as downstream effectors of SOX10-mediated migration, essential for cell adhesion and random motility, respectively. Moreover, the oncogenic activation of MAPK was necessary for increased random motility through EphA2 phosphorylation at the Ser 897 residue. We also identified IRF1 as an upstream regulator of both ITGA3 and EphA2 after the knockdown of SOX10. Notably, IRF1 suppression or the treatment with the FAK inhibitor, defactinib, significantly reduced melanoma metastasis in vivo. These findings demonstrate that the reduced expression of SOX10 promotes melanoma metastasis through the IRF1-ITGA3/EphA2-FAK pathway and highlight FAK inhibition as a potential therapeutic strategy.

SOX10通过IRF1-ITGA3/EphA2-FAK通路调控黑色素瘤转移。
黑色素瘤的异质性增加了转移的可能性。虽然以MITFlow/AXLhigh为特征的亚群与侵袭性有关,但其潜在机制尚不清楚。在本研究中,我们发现在黑色素瘤中SOX10基因敲除后,细胞迁移相关基因组显著富集。硅分析和体外分析均发现ITGA3和EPHA2是sox10介导的迁移的下游效应物,分别对细胞粘附和随机运动至关重要。此外,MAPK的致癌激活是通过EphA2在Ser 897残基上的磷酸化而增加随机运动性所必需的。我们还发现,在SOX10基因敲低后,IRF1是ITGA3和EphA2的上游调控因子。值得注意的是,IRF1抑制或FAK抑制剂defactinib治疗可显著减少体内黑色素瘤转移。这些发现表明,SOX10的表达降低通过IRF1-ITGA3/EphA2-FAK途径促进黑色素瘤转移,并强调FAK抑制是一种潜在的治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Science
Cancer Science ONCOLOGY-
CiteScore
9.90
自引率
3.50%
发文量
406
审稿时长
17 weeks
期刊介绍: Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports. Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信